title: Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
abstract: During a double-blind, randomized study in hypertensive patients, changes in blood pressure (BP) and in plasma lipid and lipoprotein levels during treatment with celiprolol were compared with those occurring during nifedipine treatment. Fifty-three patients (28 men and 25 women) with mild-to-moderate hypertension, aged 20-64 years, were studied. After a 1-month placebo run-in period, patients were randomly assigned to receive either nifedipine (40 mg daily) or celiprolol (200 mg daily) each time using a double dummy technique. After 6 weeks, dosages of each drug could be doubled. Both drugs caused similar reductions in blood pressure but after 12 weeks treatment, the percentage of decrease in diastolic BP (DBP) was more pronounced (p less than 0.01) in the nifedipine group (-18%) than in the celiprolol group (-12%). After 6 weeks, there were no differences in plasma lipids between the two treatment groups. However, the changes after 12 weeks treatment were different (p less than 0.05) between the groups, leading to lower levels of plasma esterified cholesterol, low-density lipoprotein (LDL) cholesterol and apoprotein AI, AII, and B in the celiprolol group. Plasma lecithin cholesterol acyltransferase activity (LCAT) was not modified, suggesting that reverse cholesterol transport was not affected by the drugs. In both treatment groups, a significant positive relationship was observed between changes in LDL cholesterol and apoprotein B. As compared with nifedipine, celiprolol after 12-week therapy had a rather favorable plasma lipid profile. The clinical relevance of such findings, in terms of prevention of cardiovascular complications, has yet to be established.
authors.affiliation: Hypertensie en Cardiovasculaire Revalidatie Eenheid, Katholieke Universiteit Leuven, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: van Hoof
authors.forename: J P
authors.initials: JP
authors.lastname: Desager
authors.forename: C
authors.initials: C
authors.lastname: Harvengt
authors.forename: R
authors.initials: R
authors.lastname: Fagard
authors.forename: P
authors.initials: P
authors.lastname: Lijnen
authors.forename: P
authors.initials: P
authors.lastname: Peerenboom
authors.forename: J
authors.initials: J
authors.lastname: Staessen
authors.forename: L
authors.initials: L
authors.lastname: Thijs
authors.forename: W
authors.initials: W
authors.lastname: Van Mieghem
authors.forename: A
authors.initials: A
authors.lastname: Amery
mesh_terms: D000217:Acyltransferases / Q000097:blood; D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001059:Apoproteins / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D017272:Celiprolol; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology*; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000959:Antihypertensive Agents; D001059:Apoproteins; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011412:Propanolamines; D002784:Cholesterol; D017272:Celiprolol; D000217:Acyltransferases; D009543:Nifedipine